New era in heart failure management: implementing cutting-edge therapies effectively.

Open Heart

Pontificia Bolivariana, University of Antioquia, Cardiovid Clinic, Medelin, Colombia.

Published: April 2024

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015219PMC
http://dx.doi.org/10.1136/openhrt-2024-002659DOI Listing

Publication Analysis

Top Keywords

era heart
4
heart failure
4
failure management
4
management implementing
4
implementing cutting-edge
4
cutting-edge therapies
4
therapies effectively
4
era
1
failure
1
management
1

Similar Publications

Purpose Of Review: This review summarizes the current literature on primary graft dysfunction highlighting the current definition, reviewing epidemiology, and describing donor, recipient, and perioperative risk factors in the contemporary era.

Recent Findings: PGD, in its most severe form, complicates 8% of heart transplants and portends a 1-year mortality of close to 40%. PGD is multifactorial and heterogeneous with contributions from donor and recipient risk as well as organ recovery and preservation modalities.

View Article and Find Full Text PDF

The invention of the string galvanometer by Willem Einthoven in 1901 ushered in a new era of clinical investigation. Previous instruments were capable only of rudimentary measurements that were of limited utility. Advances in physiology and engineering allowed Einthoven to construct a device that was uniquely capable of recording the minute electrical currents of the heart.

View Article and Find Full Text PDF

Background: Coronary artery disease (CAD) and atrial fibrillation (AF) often coexist, but the impact of clinical phenotypes of CAD on outcomes in AF patients in the non-vitamin K antagonist oral anticoagulant drugs (NOACs) era is less well understood.

Methods: This was a post-hoc of the GLORIA-AF registry, a global, multicenter, prospective AF registry study. Patients were divided into three groups: prior history of myocardial infarction (MI)/unstable angina group (Group 1); stable angina group (Group 2); and a control group without stable angina or history of MI/unstable angina.

View Article and Find Full Text PDF

Heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) is typically coupled with progressive left ventricular enlargement and detrimental cardiac remodeling. The management of HFrEF is comprehensive and primarily involves pharmacologic treatment using cardioprotective agents. Cardiac rehabilitation (CR) is also strongly recommended as a treatment for HFrEF.

View Article and Find Full Text PDF

Balloon atrioseptostomy for transposition of the great arteries in Europe: characteristics and outcomes.

Rev Esp Cardiol (Engl Ed)

January 2025

Pediatric Cardiology Department, M3C National reference center, Hospital Necker- Enfants Malades, Assistance Publique-Hôpitaux de Paris, University Paris Cité, Paris, France.

Introduction And Objectives: Balloon atrial septostomy (BAS) improves oxygenation in neonates with transposition of the great arteries (TGA) and restrictive foramen ovale. Currently, there is a global shortage of dedicated BAS catheters, while new unmarked catheters have recently become available at some European centers. This study aimed to characterize BAS outcomes using the currently available BAS catheters in Europe.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!